Fostering technology transfer in industrial biotechnology by academic spin-offs

Industrial biotechnology is the commercial application of biotechnology using cells or components of cells, like enzymes, for industrial production processes including consumer goods, bioenergy and biomaterials. In the last years this area has gone thr…


Why pharma's 'anti-competitive' practices may actually be good

The FTC is reportedly seeking $1 billion from pharmaceutical companies for the role in paying generic companies not to challenge their patents. Despite first appearances, these agreements for a generic company not to challenge a patent, called ‘reverse settlements’, may actually be good for innovation. The rationale for reverse settlements is discussed in my textbook, […]


Drug Patent Expirations for March 18 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for March 18 2014

TradenameApplicantGeneric NamePatent
Expiration

ACCOLATE

Astrazeneca

zafirlukast

Mar 18, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape
Go to paperABSTRACT: Patent analytical da…


Scientific American Discusses 2014 Worldview Global Biotechnology Innovation Assessment

For those who missed the live presentation, here is the discussion of the 2014 Scientific American Worldview scorecard, featuring myself, Mike May (Worldview Editorial Director), David Brancaccio ( public radio’s Marketplace), and Caroline Rugierri (Access Life Sciences). Some of the themes we discussed were: Innovation’s true “value proposition” and the ways in which investing in science has multilayered […]


Join me for a discussion on global biotechnology

Join me on Tuesday March 25th at 11am EST for a discussion of global biotechnology. I will be discussing the Scientific American Worldview project along with Mike May, the project editor, and David Brancaccio, Host of NPR’s Marketplace Morning Report. RSVP at https://plus.google.com/events/ckr9i12nbkob5ck1m6feci9bep0


Biotech Stocks Slide – Market Correction, or IPO Window Slamming Shut?

2013 and 2014 have been very good for biotechnology public markets. 35 biotechnology companies went public in 2013, and well over a dozen have gone public in the first few months of 2014. With the surge in public launches, one must ask the question: “How long can it last?” Just a few days ago Barrons’s […]


Drug Patent Expirations for March 13 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

FDA Orange Book archives from 2005 to present

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for March 13 2014

TradenameApplicantGeneric NamePatent
Expiration

KALETRA

Abbvie

lopinavir; ritonavir

Mar 13, 2014

NORVIR

Abbott

ritonavir

Mar 13, 2014

NORVIR

Abbvie

ritonavir

Mar 13, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Drug Patent Expirations for March 10 2014

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Who are the leading pharmaceutical patent challengers? A report on
Paragraph IV challenges

Advertise
here

This newsletter is
a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Drug Patent Expirations for March 10 2014

TradenameApplicantGeneric NamePatent
Expiration

IMITREX

Glaxosmithkline

sumatriptan

Mar 10, 2014

*Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details.





Instant Access to Deep Knowledge on Small-Molecule
Drugs

Subscribers have
access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data
    export
  • More…

More than 6,400 small-molecule drugs from
1,700 branded and generic pharmaceutical companies and 700 suppliers, and
more than 80,000 U.S. and international patents.

See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: